The challenge of gene therapy is to send a functioning gene into a nucleus, and to have it land in the desired spot so that it will be reproduced normally during cell division and have a lasting effect. Various methods have been developed to get genes to their targets and these include: -
- Packing genes into non-virulent viruses or inactivated viruses and injecting the gene-virus complex into the patient
- Placing the gene of interest inside a liposome - a fatty type molecule that can traverse cell membranes
A whole host of viral vectors are at the disposal genetic scientists and these include adenoviruses, retro-viruses, and adeno-associated viruses.
There are a number of risks associated with the use of viral vectors and these include a concern that once inside a cell a virus might 're-discover' its pathogenic abilities. In addition, a virus could cause a number of problems such as provoking a strong immune and inflammatory reaction.
In 1999 teenager Jesse Gelsinger became the first person to die whilst undergoing a gene therapy treatment.